Treatment response based on the emergence time of ACAs
| Time . | Group 1 . | Group 2 . | ||||
|---|---|---|---|---|---|---|
| Trisomy 8 . | −Y . | Extra Ph . | i(17)(q10) . | −7/del(7q) . | 3q26 . | |
| At CML diagnosis | ||||||
| CCyR | 4/4 (100%) | 10/14 (71%) | 4/4 (100%) | 0/2 (0%) | 0/1 (0%) | 0/2 (0%) |
| MMR | 3/4 (75%) | 9/14 (64%) | 4/4 (100%) | 0/2 (0%) | 0/1 (0%) | 0/17 (0%) |
| During the course | ||||||
| CCyR | 8/18 (44%) | 7/12 (58%) | 8/15 (53%) | 2/13 (15%) | 1/3 (33%) | 0/2 (0%) |
| MMR | 8/18 (44%) | 7/12 (58%) | 6/15 (40%) | 1/13 (8%) | 0/3 (0%) | 0/17 (0%) |
| Time . | Group 1 . | Group 2 . | ||||
|---|---|---|---|---|---|---|
| Trisomy 8 . | −Y . | Extra Ph . | i(17)(q10) . | −7/del(7q) . | 3q26 . | |
| At CML diagnosis | ||||||
| CCyR | 4/4 (100%) | 10/14 (71%) | 4/4 (100%) | 0/2 (0%) | 0/1 (0%) | 0/2 (0%) |
| MMR | 3/4 (75%) | 9/14 (64%) | 4/4 (100%) | 0/2 (0%) | 0/1 (0%) | 0/17 (0%) |
| During the course | ||||||
| CCyR | 8/18 (44%) | 7/12 (58%) | 8/15 (53%) | 2/13 (15%) | 1/3 (33%) | 0/2 (0%) |
| MMR | 8/18 (44%) | 7/12 (58%) | 6/15 (40%) | 1/13 (8%) | 0/3 (0%) | 0/17 (0%) |